JP2013519363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519363A5 JP2013519363A5 JP2012552394A JP2012552394A JP2013519363A5 JP 2013519363 A5 JP2013519363 A5 JP 2013519363A5 JP 2012552394 A JP2012552394 A JP 2012552394A JP 2012552394 A JP2012552394 A JP 2012552394A JP 2013519363 A5 JP2013519363 A5 JP 2013519363A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- proinflammatory
- mature
- proinflammatory mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 Dendritic Cells Anatomy 0.000 claims 12
- 230000000770 pro-inflamatory Effects 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 229960002986 dinoprostone Drugs 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000011614 malignant glioma Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 102100009686 CXCL9 Human genes 0.000 claims 1
- 101700052645 CXCL9 Proteins 0.000 claims 1
- 101700046422 IFNA Proteins 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 229950010550 Resiquimod Drugs 0.000 claims 1
- 101710044433 SAG Proteins 0.000 claims 1
- 231100000617 Superantigen Toxicity 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Claims (10)
- 物質ポリイノシン酸−ポリシチジル酸ナトリウム塩(ポリ−I:C)、レシキモド(R848)およびインターフェロンγ(IFN−γ)を用いた処理によってエキソビボで成熟へとすでに刺激された炎症誘発性樹状細胞(DC)であって、炎症誘発性成熟DCの源以外の個体における癌の処置において使用するための、プロスタグランジンE2(PGE2)を伴わない、腫瘍内に注入される炎症誘発性成熟DC。
- 加えて、インターフェロンα(IFN−α)、インターロイキン1、β(IL−1β)および腫瘍壊死因子α(TNF−α)からなる群から選択される物質のうちの少なくとも1つですでに刺激された、請求項1に記載の炎症誘発性成熟DC。
- 刺激を取り除いた後24時間の間に、少なくとも25 000pg IL−12/mL/10 6 細胞、少なくとも100 000pg CXCL9/mL/10 6 細胞、および少なくとも40 000pg CCL3/mL/10 6 細胞を産生する、請求項1または請求項2に記載の炎症誘発性成熟DC。
- 刺激を取り除いた後24時間の間に、少なくとも2 000pg TNF−α/mL/10 6 細胞および少なくとも500pg IL−1β/mL/10 6 細胞をさらに産生する、請求項1から請求項3のいずれか1項に記載の炎症誘発性成熟DC。
- 炎症誘発性成熟DCまたは末梢血単核球(PBMC)の源以外の個体における癌の処置において使用するための、請求項1から請求項4のいずれか1項に記載の炎症誘発性成熟DCと、前記PBMCとを含む、腫瘍内に注入される組成物。
- 超抗原をさらに含む、請求項5に記載の組成物。
- 薬学的に許容できる賦形剤をさらに含む、請求項5に記載の組成物。
- 前記癌は、乳癌、前立腺癌、腎癌、腸癌、悪性神経膠腫、骨肉腫、悪性黒色腫、膵臓癌、悪性リンパ腫および食道癌からなる群から選択される、請求項1から請求項7のいずれか1項に記載の炎症誘発性成熟DCまたは組成物。
- 炎症誘発性成熟DCの源以外の個体における癌の処置のため腫瘍内に注入される医薬の製造のための、請求項1から請求項4のいずれか1項に記載の炎症誘発性成熟DCの使用方法。
- 前記癌は、乳癌、前立腺癌、腎癌、腸癌、悪性神経膠腫、骨肉腫、悪性黒色腫、膵臓癌、悪性リンパ腫および食道癌からなる群から選択される、請求項9に記載の使用方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30315310P | 2010-02-10 | 2010-02-10 | |
SE1050133-6 | 2010-02-10 | ||
US61/303,153 | 2010-02-10 | ||
SE1050133 | 2010-02-10 | ||
PCT/EP2011/051952 WO2011098516A1 (en) | 2010-02-10 | 2011-02-10 | Improved composition for inhibiting tumor cell proliferation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013519363A JP2013519363A (ja) | 2013-05-30 |
JP2013519363A5 true JP2013519363A5 (ja) | 2014-03-06 |
JP5855018B2 JP5855018B2 (ja) | 2016-02-09 |
Family
ID=43903832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012552394A Expired - Fee Related JP5855018B2 (ja) | 2010-02-10 | 2011-02-10 | 腫瘍細胞増殖を阻害するための改善された組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9034317B2 (ja) |
EP (1) | EP2534242B1 (ja) |
JP (1) | JP5855018B2 (ja) |
KR (1) | KR101770785B1 (ja) |
CN (1) | CN102782123B (ja) |
BR (1) | BR112012019267B1 (ja) |
DK (1) | DK2534242T3 (ja) |
ES (1) | ES2581277T3 (ja) |
HU (1) | HUE028352T2 (ja) |
PL (1) | PL2534242T3 (ja) |
RU (1) | RU2565542C2 (ja) |
SI (1) | SI2534242T1 (ja) |
WO (1) | WO2011098516A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2668816C2 (ru) | 2012-12-18 | 2018-10-02 | Иммуникум Аб | Совместная дифференцировка моноцитов от аллогенных доноров |
EP3291821A4 (en) * | 2015-05-07 | 2019-03-20 | Baylor College of Medicine | DENDRITIC CELL IMMUNOTHERAPY |
CN105695403A (zh) * | 2015-12-31 | 2016-06-22 | 深圳市中美康士生物科技有限公司 | 一种杀伤性免疫细胞的培养方法及其应用 |
CN105462926A (zh) * | 2015-12-31 | 2016-04-06 | 深圳市中美康士生物科技有限公司 | 一种免疫细胞瘤苗的制备方法及其应用 |
CN107574149B (zh) * | 2016-07-05 | 2022-02-18 | 上海细胞治疗研究院 | 一种树突状细胞的促成熟方法及其用途 |
CN106085960A (zh) * | 2016-07-28 | 2016-11-09 | 广州赛莱拉干细胞科技股份有限公司 | 一种培养dc细胞的培养基及培养方法 |
CA3037882A1 (en) | 2016-09-23 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
GB201711379D0 (en) * | 2017-07-14 | 2017-08-30 | Univ Cape Town | Maturation of dendritic cells |
PL3460052T3 (pl) | 2017-09-20 | 2020-05-18 | Immunicum Ab | Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
CA2509058A1 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
WO2008110569A1 (en) * | 2007-03-12 | 2008-09-18 | Bioneer A/S | Method for determination of immunomodulatory effect |
HUE024479T2 (en) * | 2007-10-08 | 2016-01-28 | Intrexon Corp | Genetically altered dendritic cells and uses for cancer treatment |
US8728806B2 (en) * | 2008-12-06 | 2014-05-20 | The Board Of Regents, The University Of Texas System | Methods and compositions related to Th-1 dendritic cells |
CN101481677B (zh) * | 2009-01-22 | 2011-12-14 | 复旦大学附属华山医院 | 体外刺激树突状细胞成熟的方法 |
-
2011
- 2011-02-10 CN CN201180008012.3A patent/CN102782123B/zh not_active Expired - Fee Related
- 2011-02-10 DK DK11702471.1T patent/DK2534242T3/en active
- 2011-02-10 WO PCT/EP2011/051952 patent/WO2011098516A1/en active Application Filing
- 2011-02-10 KR KR1020127021390A patent/KR101770785B1/ko active IP Right Grant
- 2011-02-10 US US13/522,741 patent/US9034317B2/en active Active
- 2011-02-10 EP EP11702471.1A patent/EP2534242B1/en active Active
- 2011-02-10 PL PL11702471.1T patent/PL2534242T3/pl unknown
- 2011-02-10 SI SI201130868A patent/SI2534242T1/sl unknown
- 2011-02-10 HU HUE11702471A patent/HUE028352T2/en unknown
- 2011-02-10 ES ES11702471.1T patent/ES2581277T3/es active Active
- 2011-02-10 RU RU2012137173/10A patent/RU2565542C2/ru active
- 2011-02-10 BR BR112012019267-1A patent/BR112012019267B1/pt active IP Right Grant
- 2011-02-10 JP JP2012552394A patent/JP5855018B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013519363A5 (ja) | ||
RU2015154737A (ru) | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности | |
JP2006525995A5 (ja) | ||
RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
RU2012137173A (ru) | Улучшенная композиция для ингибирования пролиферации опухолевых клеток | |
EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
RU2014111662A (ru) | Лечение кахексии | |
HRP20141230T1 (hr) | Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica | |
JP2018522880A5 (ja) | ||
NO20082566L (no) | Kombinasjon av AZ2171 og permetrexed | |
RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
JP2012506394A5 (ja) | ||
NO20064755L (no) | Kombinasjonsterapi | |
JP2013507945A5 (ja) | ||
JP2013520271A5 (ja) | ||
DE60226517D1 (de) | Dipeptidyl peptidase iv inhibitoren zur senkung der chronische gewichtszunahme | |
SI1530628T1 (sl) | Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine | |
JP2017061488A5 (ja) | ||
JP2012504161A5 (ja) | ||
IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
JP2013505939A5 (ja) | ||
RU2015139515A (ru) | Комбинированное лечение | |
WO2013096732A3 (en) | Methods of treating or preventing viral diseases by blocking interleukin-21 | |
RU2012114023A (ru) | Способ стимуляции эндогенной продукции цитокинов и гемопоэтических факторов |